Cargando…

Osteoid cell-derived chemokines drive bone-metastatic prostate cancer

One of the greatest challenges in improving prostate cancer (PCa) survival is in designing new therapies to effectively target bone metastases. PCa regulation of the bone environment has been well characterized; however, bone-targeted therapies have little impact on patient survival, demonstrating a...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Catherine S., Cook, Leah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070788/
https://www.ncbi.nlm.nih.gov/pubmed/37025604
http://dx.doi.org/10.3389/fonc.2023.1100585
_version_ 1785019068678406144
author Johnson, Catherine S.
Cook, Leah M.
author_facet Johnson, Catherine S.
Cook, Leah M.
author_sort Johnson, Catherine S.
collection PubMed
description One of the greatest challenges in improving prostate cancer (PCa) survival is in designing new therapies to effectively target bone metastases. PCa regulation of the bone environment has been well characterized; however, bone-targeted therapies have little impact on patient survival, demonstrating a need for understanding the complexities of the tumor-bone environment. Many factors contribute to creating a favorable microenvironment for prostate tumors in bone, including cell signaling proteins produced by osteoid cells. Specifically, there has been extensive evidence from both past and recent studies that emphasize the importance of chemokine signaling in promoting PCa progression in the bone environment. Chemokine-focused strategies present promising therapeutic options for treating bone metastasis. These signaling pathways are complex, with many being produced by (and exerting effects on) a plethora of different cell types, including stromal and tumor cells of the prostate tumor-bone microenvironment. ​This review highlights an underappreciated molecular family that should be interrogated for treatment of bone metastatic prostate cancer (BM-PCa).
format Online
Article
Text
id pubmed-10070788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100707882023-04-05 Osteoid cell-derived chemokines drive bone-metastatic prostate cancer Johnson, Catherine S. Cook, Leah M. Front Oncol Oncology One of the greatest challenges in improving prostate cancer (PCa) survival is in designing new therapies to effectively target bone metastases. PCa regulation of the bone environment has been well characterized; however, bone-targeted therapies have little impact on patient survival, demonstrating a need for understanding the complexities of the tumor-bone environment. Many factors contribute to creating a favorable microenvironment for prostate tumors in bone, including cell signaling proteins produced by osteoid cells. Specifically, there has been extensive evidence from both past and recent studies that emphasize the importance of chemokine signaling in promoting PCa progression in the bone environment. Chemokine-focused strategies present promising therapeutic options for treating bone metastasis. These signaling pathways are complex, with many being produced by (and exerting effects on) a plethora of different cell types, including stromal and tumor cells of the prostate tumor-bone microenvironment. ​This review highlights an underappreciated molecular family that should be interrogated for treatment of bone metastatic prostate cancer (BM-PCa). Frontiers Media S.A. 2023-03-21 /pmc/articles/PMC10070788/ /pubmed/37025604 http://dx.doi.org/10.3389/fonc.2023.1100585 Text en Copyright © 2023 Johnson and Cook https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Johnson, Catherine S.
Cook, Leah M.
Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title_full Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title_fullStr Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title_full_unstemmed Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title_short Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
title_sort osteoid cell-derived chemokines drive bone-metastatic prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070788/
https://www.ncbi.nlm.nih.gov/pubmed/37025604
http://dx.doi.org/10.3389/fonc.2023.1100585
work_keys_str_mv AT johnsoncatherines osteoidcellderivedchemokinesdrivebonemetastaticprostatecancer
AT cookleahm osteoidcellderivedchemokinesdrivebonemetastaticprostatecancer